Bayer stock holds near EUR 49 as Q2 figures shape the outlook

Published on 09/22/2026 at 11:35 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Bayer stock closed at EUR 49.03 on September 21, 2026, with a 52-week high of EUR 53.92. Q2 revenue reached EUR 10.87 billion.

Flatlay auf weißem Untergrund: weiße runde Tabletten, Marmorstößel, grünes Pflanzenblatt, Glasflakon und gedrucktes DNA-Doppelhelix-Diagramm; Beschriftungskarte mit Text PHARMA — Top-down-Arrangement: weiße Tabletten, Mörser, grünes Blatt, DNA-Diagramm, Beschriftungskarte PHARMA, Illustration mit AI erstellt.

Bayer stock closed at EUR 49.03 on Xetra on September 21, 2026, after gaining EUR 0.94, or 1.95 percent, during the session. The price remains EUR 4.89, or 9.97 percent, below the 52-week high of EUR 53.92 recorded on July 3, 2026, while the 52-week low stands at EUR 25.78 from November 7, 2025.

Second quarter sets the scale

Bayer AG reported group revenue of EUR 10.87 billion for the second quarter of 2026 and adjusted EBITDA of EUR 2.14 billion for the same period, according to the company figures cited on September 21, 2026. The operating result represents about 19.7 percent of quarterly revenue, providing a concrete benchmark for the earnings profile investors are weighing against the company's legal and investment burdens.

Adjusted earnings per share came to EUR 0.23 in the quarter ended June 30, 2026, according to Ad-hoc-news on September 21, 2026. The combination of revenue, EBITDA and EPS gives the latest report a more useful investor frame than the share price alone.

Stivarga disposal changes the mix

The portfolio adjustment is visible in the product numbers. Stivarga generated EUR 148 million in revenue during the first half of 2026, down from EUR 181 million in the prior-year period, a decline of EUR 33 million or 18.2 percent, according to Ad-hoc-news on September 21, 2026. That comparison shows why the transaction matters operationally: the asset is becoming a smaller contributor before the broader portfolio effect is fully visible.

Crop Science and Pharma continue to determine the group's earnings balance, while the second-quarter revenue of EUR 10.87 billion supplies the latest group-level reference point. The share price is still EUR 23.25 above its 52-week low, meaning the recovery from the November level has been substantial even though the stock has not retested its July peak.

Stock stays below yearly high

Market data from September 21, 2026 show a closing price of EUR 49.03, a session high of EUR 49.26, a session low of EUR 47.98 and volume of 1,456,538 shares. Market capitalization was EUR 48.168 billion on the same date, and the current price sat 47.42 percent above the 52-week low of EUR 25.78.

For investors, the key tension is visible in the figures: quarterly revenue reached EUR 10.87 billion, yet Stivarga first-half revenue fell 18.2 percent year over year. Bayer stock therefore combines a materially higher position than its 52-week low with a portfolio transition that still requires operating execution.